by Pete Celano | Jan 19, 2026 | Blog
ALD (Alcohol-Associated Liver Disease) and MetALD (Metabolic Dysfunction- and Alcohol-Associated Liver Disease) are classifications for liver conditions, with ALD involving heavy drinking and MetALD defining liver disease in individuals with Metabolic...
by Pete Celano | Jan 15, 2026 | Blog
Important article: “Liver Cancer Treatment Landscape Shifts Rapidly, but Best Sequencing Still Unclear — Real-world analysis shows liver function drives survival; only 20% reach second-line therapy,” from MedPage Today (12/30/2025). Summary: Real-World HCC...
by Pete Celano | Jan 11, 2026 | Blog
We’re in times of a dietary shift towards whole, nutrient-dense foods, emphasizing prioritizing protein, healthy fats (from sources like meat, dairy, nuts, avocados), whole grains, and produce, while sharply reducing ultra-processed foods, added...
by Pete Celano | Jan 7, 2026 | Blog, Press
Press release is here and also below: LiverRight Announces Contactless Remote Patient Monitoring Offering LiverRight (Jaundice Classifier Can Detect Potential Liver Disease via the Camera Utilized in the Actual Telemedicine Visit Itself) LiverRight Announces...
by Pete Celano | Jan 2, 2026 | Blog
As of early 2026, the “new” story in HCC drugs is less about a single brand-new molecule and more about front-line regimen changes + maturation of immunotherapy data + expansion of combo strategies (especially systemic + locoregional). What’s newly different heading...
